Sermorelin

What it is

Sermorelin is a synthetic copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that tells the pituitary to release growth hormone. Those 29 amino acids are the fully active portion of the 44-amino-acid hormone. It was approved in the 1990s as Geref, as an injection to test pituitary function and to treat children whose growth hormone secretion was inadequate. The manufacturer stopped making Geref in 2008, and no company has brought a sermorelin product back to market. ¹⁰

Because the FDA determined Geref was not pulled for safety or effectiveness reasons, compounding pharmacies may prepare sermorelin, and it has become a staple of telehealth and anti-aging clinics, often combined with growth hormone secretagogues such as ipamorelin or GHRP-2. A 2026 review of performance peptides places sermorelin in the tier of compounds with regulatory-grade data for a different indication and online protocols that have never been tested. ¹¹⁰

How it works

GHRH binds receptors on somatotroph cells in the pituitary and triggers pulses of growth hormone release. Growth hormone then acts on the liver and other tissues to produce IGF-1, which mediates most of its effects on growth and metabolism. Because sermorelin works through the pituitary, the body's feedback loops remain in place: somatostatin, the hormone that shuts off growth hormone release, still acts when levels are high, which is the basis of the claim that sermorelin cannot drive growth hormone as high as injected growth hormone can. Growth hormone secretion declines steadily from early adulthood, a process sometimes called the somatopause, and part of that decline reflects reduced hypothalamic GHRH output, so GHRH replacement is a logical idea. In a 1989 experiment, repeated GHRH dosing in healthy men aged 65 to 78 restored the blunted growth hormone response to a GHRH test. ¹⁵¹³¹⁴

What human research shows

Sermorelin itself has almost no modern trial data. A 2017 retrospective chart review of men on testosterone therapy who were prescribed sermorelin together with GHRP-2 and GHRP-6 found that in the 14 men who met compliance criteria, IGF-1 rose from a mean of about 160 to about 240 ng/mL over roughly four months. There was no control group, the regimen combined three drugs, and no body composition outcome was measured. ⁶

The body composition claims come from tesamorelin, a stabilized version of full-length GHRH, in people with HIV and antiretroviral-related belly fat. In a 412-patient randomized trial, tesamorelin cut visceral fat by 15 percent over 26 weeks while placebo patients gained 5 percent, and improved triglycerides. A pooled analysis of two phase 3 trials (806 patients) confirmed the visceral fat reduction, showed it was maintained at 52 weeks in those who stayed on drug, and found no change in subcutaneous fat. A secondary analysis found small increases in trunk muscle density and area. In 60 obese adults without HIV who had low growth hormone secretion, 12 months of tesamorelin reduced visceral fat and carotid artery wall thickness without worsening glucose. A 2026 meta-analysis of five tesamorelin trials in HIV confirmed the visceral fat, liver fat and lean mass effects. Whether compounded sermorelin at clinic doses does any of this has not been tested. ^2341112

The sleep claims rest on small physiology studies with GHRH given intravenously overnight. In 7 young men, four pulses of GHRH increased slow-wave sleep from 14 to 20 percent of the night and blunted overnight cortisol. In another study, a GHRH bolus given during the third REM period produced a large increase in slow-wave sleep. In 13 healthy adults in their late 60s, GHRH reduced night-time awakenings but had much less effect on slow-wave sleep than in the young, and did not change cortisol. These are single-night laboratory experiments, not trials of nightly injections. ⁷⁸⁹

Safety

Sermorelin has a long record of single-dose diagnostic use. The concern with adult anti-aging use is the hormone it raises: growth hormone and IGF-1 excess are tied to insulin resistance, fluid retention, joint pain and carpal tunnel syndrome, and IGF-1 promotes cell growth, which is why a theoretical cancer risk is raised whenever the axis is stimulated long term. The 2026 review of performance peptides lists endocrine disturbances, dysglycemia, fluid retention, musculoskeletal pain and injection site reactions as the adverse effects clinicians encounter in users of this class, and notes the added uncertainty of compounded or unregulated products of unknown composition. No long-term safety study of sermorelin in healthy adults exists. ¹¹²